In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What New Cancer Pathway Programs Mean For The Drug Industry

Executive Summary

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

You may also be interested in...



Recognizing Patterns Of Competition In Mechanistically Informed Markets

As pharmaceutical companies enjoy a growing and shared base of biological understanding, savvy development decision making and effective commercial positioning have become prerequisites for commercial success. Recurring patterns exist across markets where competition is dominated by products that hit a single or related set of molecular targets; smart developers can recognize these patterns to developed better clinical strategies and improve targeting of increasingly precious R&D and business development resources.

Oncologists Reject Reps’ Advances, While Pharma Keeps Paying The Tab

Oncologists are the most restrictive physicians to pharma sales reps, according to a report by ZS Associates. Oncologists permit reps less than one visit a month to educate them about new drugs, but pharma continues to waste between $1 billion and $1.5 billion on infeasible sales calls.

Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say

Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel